Matthew Sikora
Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Lobular | 12 | 2026 | 59 | 4.390 |
Why?
| | Breast Neoplasms | 26 | 2026 | 2418 | 2.960 |
Why?
| | Receptors, Estrogen | 10 | 2025 | 406 | 2.250 |
Why?
| | Wnt4 Protein | 4 | 2024 | 19 | 1.960 |
Why?
| | Antineoplastic Agents, Hormonal | 6 | 2025 | 196 | 1.420 |
Why?
| | Estrogens | 7 | 2025 | 364 | 1.350 |
Why?
| | Cell Cycle Proteins | 3 | 2026 | 630 | 1.300 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2026 | 429 | 1.290 |
Why?
| | Estrogen Receptor alpha | 9 | 2023 | 154 | 1.230 |
Why?
| | Mammary Glands, Human | 2 | 2026 | 71 | 1.100 |
Why?
| | Drug Resistance, Neoplasm | 9 | 2025 | 893 | 0.960 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2026 | 139 | 0.940 |
Why?
| | Cadherins | 3 | 2026 | 202 | 0.920 |
Why?
| | Gene Expression Regulation, Neoplastic | 13 | 2026 | 1432 | 0.820 |
Why?
| | Trans-Activators | 1 | 2026 | 372 | 0.790 |
Why?
| | DNA Repair | 1 | 2026 | 255 | 0.790 |
Why?
| | Antigens, CD | 1 | 2026 | 560 | 0.770 |
Why?
| | Tamoxifen | 7 | 2021 | 193 | 0.760 |
Why?
| | Cell Line, Tumor | 18 | 2026 | 3545 | 0.740 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 100 | 0.720 |
Why?
| | Genital Diseases, Female | 1 | 2021 | 31 | 0.670 |
Why?
| | Genitalia, Female | 1 | 2021 | 43 | 0.660 |
Why?
| | MCF-7 Cells | 10 | 2021 | 133 | 0.660 |
Why?
| | Nuclear Proteins | 1 | 2026 | 740 | 0.650 |
Why?
| | Cell Proliferation | 12 | 2021 | 2502 | 0.630 |
Why?
| | Estradiol | 7 | 2023 | 517 | 0.620 |
Why?
| | Spinal Curvatures | 1 | 2020 | 7 | 0.620 |
Why?
| | Epithelial Cells | 1 | 2026 | 1119 | 0.620 |
Why?
| | Wnt3A Protein | 1 | 2019 | 11 | 0.600 |
Why?
| | Acyltransferases | 1 | 2019 | 78 | 0.590 |
Why?
| | Psychological Tests | 1 | 2020 | 127 | 0.580 |
Why?
| | Ovarian Neoplasms | 6 | 2024 | 604 | 0.580 |
Why?
| | Women's Health | 1 | 2021 | 317 | 0.570 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 211 | 0.550 |
Why?
| | Spine | 1 | 2020 | 184 | 0.540 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2017 | 36 | 0.500 |
Why?
| | Orthopedic Procedures | 1 | 2020 | 260 | 0.500 |
Why?
| | Receptors, Mineralocorticoid | 1 | 2016 | 11 | 0.500 |
Why?
| | Anxiety Disorders | 1 | 2020 | 354 | 0.490 |
Why?
| | Serum | 1 | 2016 | 58 | 0.470 |
Why?
| | Receptors, Androgen | 1 | 2016 | 149 | 0.450 |
Why?
| | Signal Transduction | 8 | 2024 | 5246 | 0.440 |
Why?
| | Receptors, Glucocorticoid | 1 | 2016 | 132 | 0.440 |
Why?
| | Receptors, Progesterone | 1 | 2016 | 242 | 0.440 |
Why?
| | Neoplasm Invasiveness | 6 | 2020 | 504 | 0.410 |
Why?
| | Aromatase Inhibitors | 2 | 2018 | 81 | 0.390 |
Why?
| | Membrane Proteins | 1 | 2019 | 1130 | 0.380 |
Why?
| | Phthalazines | 2 | 2026 | 64 | 0.360 |
Why?
| | Female | 36 | 2026 | 79499 | 0.360 |
Why?
| | Deep Brain Stimulation | 3 | 2020 | 223 | 0.360 |
Why?
| | Tumor Microenvironment | 3 | 2024 | 747 | 0.350 |
Why?
| | Cytochrome P-450 CYP2D6 | 4 | 2017 | 33 | 0.340 |
Why?
| | Humans | 48 | 2026 | 146342 | 0.340 |
Why?
| | Gene Expression | 2 | 2014 | 1463 | 0.340 |
Why?
| | Benzoxazines | 1 | 2010 | 31 | 0.320 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 37 | 0.310 |
Why?
| | Paraffin Embedding | 1 | 2010 | 33 | 0.310 |
Why?
| | Risk Assessment | 1 | 2020 | 3712 | 0.310 |
Why?
| | Genotyping Techniques | 1 | 2010 | 74 | 0.310 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2010 | 89 | 0.310 |
Why?
| | Psoriasis | 2 | 2021 | 110 | 0.300 |
Why?
| | Androstane-3,17-diol | 1 | 2008 | 2 | 0.280 |
Why?
| | Gossypol | 1 | 2008 | 2 | 0.280 |
Why?
| | Models, Biological | 2 | 2012 | 1761 | 0.260 |
Why?
| | Carcinoma, Ductal, Breast | 3 | 2022 | 92 | 0.240 |
Why?
| | Epithelial-Mesenchymal Transition | 2 | 2026 | 219 | 0.240 |
Why?
| | Breast | 3 | 2022 | 155 | 0.230 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2025 | 2 | 0.220 |
Why?
| | Cell Lineage | 1 | 2026 | 377 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2026 | 930 | 0.210 |
Why?
| | Antioxidants | 1 | 2008 | 544 | 0.210 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2026 | 314 | 0.210 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.200 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 90 | 0.200 |
Why?
| | DNA | 1 | 2010 | 1421 | 0.200 |
Why?
| | Neoplasms | 2 | 2010 | 2954 | 0.190 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 193 | 0.180 |
Why?
| | Selective Estrogen Receptor Modulators | 3 | 2017 | 33 | 0.180 |
Why?
| | Ligands | 1 | 2024 | 678 | 0.170 |
Why?
| | Sex Differentiation | 1 | 2021 | 11 | 0.170 |
Why?
| | Sexual Development | 1 | 2021 | 17 | 0.170 |
Why?
| | Animals | 9 | 2026 | 38107 | 0.160 |
Why?
| | Analgesics, Opioid | 2 | 2020 | 1221 | 0.160 |
Why?
| | RNA Interference | 2 | 2019 | 472 | 0.160 |
Why?
| | Mice | 7 | 2026 | 18297 | 0.160 |
Why?
| | Neuroma, Acoustic | 1 | 2021 | 50 | 0.160 |
Why?
| | Protein Binding | 2 | 2016 | 2244 | 0.160 |
Why?
| | Genotype | 3 | 2017 | 1879 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 69 | 0.150 |
Why?
| | Laminectomy | 1 | 2020 | 30 | 0.150 |
Why?
| | Diskectomy | 1 | 2020 | 23 | 0.150 |
Why?
| | Uterus | 1 | 2021 | 227 | 0.150 |
Why?
| | Cell Survival | 2 | 2016 | 1105 | 0.150 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 112 | 0.150 |
Why?
| | Preoperative Period | 1 | 2020 | 157 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2020 | 82 | 0.150 |
Why?
| | Paracrine Communication | 1 | 2019 | 67 | 0.150 |
Why?
| | Snail Family Transcription Factors | 1 | 2019 | 18 | 0.150 |
Why?
| | Coculture Techniques | 1 | 2019 | 245 | 0.140 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 429 | 0.140 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 2240 | 0.140 |
Why?
| | Gene Amplification | 1 | 2019 | 116 | 0.140 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 88 | 0.140 |
Why?
| | Gene Expression Profiling | 2 | 2018 | 1792 | 0.140 |
Why?
| | Clinical Protocols | 1 | 2020 | 282 | 0.140 |
Why?
| | Protein Transport | 1 | 2019 | 443 | 0.130 |
Why?
| | Estrogen Receptor Antagonists | 1 | 2017 | 4 | 0.130 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 209 | 0.130 |
Why?
| | Endometriosis | 1 | 2018 | 58 | 0.130 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 233 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 475 | 0.130 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 633 | 0.130 |
Why?
| | Transcriptome | 2 | 2021 | 1068 | 0.120 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 32 | 0.120 |
Why?
| | Machine Learning | 2 | 2020 | 594 | 0.120 |
Why?
| | Middle Aged | 11 | 2024 | 36619 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2012 | 2022 | 0.120 |
Why?
| | Fishes | 1 | 2017 | 111 | 0.120 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 2219 | 0.120 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 457 | 0.120 |
Why?
| | Inflammation | 2 | 2020 | 2919 | 0.120 |
Why?
| | Piperazines | 1 | 2019 | 368 | 0.120 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 612 | 0.120 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1242 | 0.120 |
Why?
| | Androstenes | 1 | 2016 | 16 | 0.120 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2016 | 13 | 0.120 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 104 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 371 | 0.120 |
Why?
| | Proto-Oncogene Proteins | 1 | 2019 | 616 | 0.110 |
Why?
| | Surgical Wound Infection | 1 | 2019 | 349 | 0.110 |
Why?
| | Neoplasms, Glandular and Epithelial | 1 | 2016 | 52 | 0.110 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1488 | 0.110 |
Why?
| | Reproduction | 1 | 2017 | 209 | 0.110 |
Why?
| | Algorithms | 2 | 2020 | 1849 | 0.110 |
Why?
| | Comorbidity | 1 | 2020 | 1665 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 533 | 0.110 |
Why?
| | Prognosis | 5 | 2024 | 4351 | 0.100 |
Why?
| | Pilot Projects | 1 | 2020 | 1888 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 928 | 0.100 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2014 | 59 | 0.100 |
Why?
| | Retrospective Studies | 6 | 2021 | 17438 | 0.090 |
Why?
| | Amyloid beta-Peptides | 1 | 2015 | 251 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1998 | 0.090 |
Why?
| | Aged | 7 | 2024 | 26432 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1339 | 0.090 |
Why?
| | NF-kappa B | 1 | 2016 | 674 | 0.090 |
Why?
| | Mutation | 2 | 2021 | 4093 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1160 | 0.090 |
Why?
| | Smoking | 1 | 2019 | 1486 | 0.090 |
Why?
| | Phenotype | 2 | 2018 | 3206 | 0.080 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 634 | 0.080 |
Why?
| | Quality Improvement | 1 | 2020 | 1354 | 0.080 |
Why?
| | Blotting, Western | 2 | 2015 | 1177 | 0.080 |
Why?
| | Gynecomastia | 1 | 2010 | 6 | 0.080 |
Why?
| | Inhibitory Concentration 50 | 1 | 2010 | 90 | 0.080 |
Why?
| | Cyclopropanes | 1 | 2010 | 83 | 0.080 |
Why?
| | Microarray Analysis | 1 | 2010 | 117 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2021 | 3034 | 0.080 |
Why?
| | Alkynes | 1 | 2010 | 67 | 0.080 |
Why?
| | Formaldehyde | 1 | 2010 | 66 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 974 | 0.080 |
Why?
| | Brain Injuries, Traumatic | 1 | 2015 | 466 | 0.070 |
Why?
| | Alzheimer Disease | 1 | 2015 | 641 | 0.070 |
Why?
| | Polyunsaturated Alkamides | 1 | 2008 | 7 | 0.070 |
Why?
| | Cell Cycle Checkpoints | 2 | 2019 | 97 | 0.070 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 14 | 0.070 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1041 | 0.070 |
Why?
| | Genetic Association Studies | 1 | 2010 | 379 | 0.070 |
Why?
| | Arachidonic Acids | 1 | 2008 | 42 | 0.070 |
Why?
| | Pregnancy | 1 | 2021 | 7230 | 0.070 |
Why?
| | Hot Flashes | 1 | 2009 | 92 | 0.070 |
Why?
| | Oxidants | 1 | 2008 | 100 | 0.070 |
Why?
| | Phosphorylation | 1 | 2012 | 1724 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2020 | 11821 | 0.060 |
Why?
| | Acetylcysteine | 1 | 2008 | 139 | 0.060 |
Why?
| | Drug Synergism | 1 | 2008 | 354 | 0.060 |
Why?
| | Heterografts | 2 | 2019 | 143 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1031 | 0.060 |
Why?
| | Androgens | 1 | 2008 | 179 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 752 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 1 | 2012 | 983 | 0.060 |
Why?
| | Male | 6 | 2020 | 73396 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2008 | 610 | 0.050 |
Why?
| | Brain | 2 | 2015 | 2991 | 0.050 |
Why?
| | Survival Rate | 2 | 2020 | 2092 | 0.050 |
Why?
| | Patient Compliance | 1 | 2009 | 589 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2024 | 313 | 0.050 |
Why?
| | Patient Discharge | 2 | 2020 | 997 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2010 | 4118 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2814 | 0.050 |
Why?
| | Databases, Genetic | 1 | 2023 | 239 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2010 | 944 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2016 | 1712 | 0.040 |
Why?
| | Biology | 1 | 2022 | 90 | 0.040 |
Why?
| | Microsurgery | 1 | 2021 | 75 | 0.040 |
Why?
| | Etanercept | 1 | 2020 | 60 | 0.040 |
Why?
| | Ustekinumab | 1 | 2020 | 17 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 53 | 0.040 |
Why?
| | Apoptosis | 2 | 2019 | 2439 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2020 | 5439 | 0.040 |
Why?
| | Ubiquitination | 1 | 2020 | 119 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2488 | 0.040 |
Why?
| | Proteolysis | 1 | 2020 | 174 | 0.040 |
Why?
| | Narcotics | 1 | 2020 | 57 | 0.040 |
Why?
| | Adult | 5 | 2021 | 41087 | 0.040 |
Why?
| | Movement Disorders | 1 | 2019 | 68 | 0.040 |
Why?
| | Oxysterols | 1 | 2018 | 2 | 0.040 |
Why?
| | Indazoles | 1 | 2019 | 86 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 355 | 0.030 |
Why?
| | Adherens Junctions | 1 | 2018 | 24 | 0.030 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2018 | 11 | 0.030 |
Why?
| | Sterol Regulatory Element Binding Protein 1 | 1 | 2018 | 56 | 0.030 |
Why?
| | Morphine | 1 | 2020 | 171 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2019 | 192 | 0.030 |
Why?
| | Collagen Type I | 1 | 2018 | 144 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2020 | 314 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 882 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 225 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 487 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1271 | 0.030 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2018 | 447 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 352 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2016 | 76 | 0.030 |
Why?
| | DNA, Neoplasm | 1 | 2016 | 160 | 0.030 |
Why?
| | Risk Factors | 2 | 2020 | 10921 | 0.030 |
Why?
| | Mice, SCID | 1 | 2016 | 360 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 511 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 530 | 0.030 |
Why?
| | Length of Stay | 1 | 2021 | 1358 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 970 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 693 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 907 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2018 | 565 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2113 | 0.030 |
Why?
| | Survival Analysis | 1 | 2017 | 1378 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 951 | 0.030 |
Why?
| | Genome | 1 | 2016 | 307 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 846 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 444 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2921 | 0.020 |
Why?
| | Behavior, Animal | 1 | 2015 | 531 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1163 | 0.020 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 12 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2867 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2400 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2134 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 183 | 0.020 |
Why?
| | DNA Primers | 1 | 2010 | 487 | 0.020 |
Why?
| | 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 6 | 0.020 |
Why?
| | Microsomes | 1 | 2008 | 33 | 0.020 |
Why?
| | Mice, Nude | 1 | 2010 | 668 | 0.020 |
Why?
| | Hydroxylation | 1 | 2008 | 47 | 0.020 |
Why?
| | Epoxy Compounds | 1 | 2008 | 31 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2008 | 101 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2016 | 2791 | 0.020 |
Why?
| | Endocannabinoids | 1 | 2008 | 55 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2010 | 1244 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2123 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2015 | 4580 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2015 | 6034 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 14330 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3416 | 0.010 |
Why?
| | Mitochondria | 1 | 2008 | 997 | 0.010 |
Why?
| | Cohort Studies | 1 | 2009 | 6077 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 7109 | 0.010 |
Why?
| | Prospective Studies | 1 | 2009 | 8123 | 0.010 |
Why?
|
|
Sikora's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|